Farallon Capital Management’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.22M | Sell |
715,000
-1,855,700
| -72% | -$5.77M | 0.01% | 79 |
|
|
2025
Q1 | $8.69M | Hold |
2,570,700
| – | – | 0.04% | 71 |
|
|
2024
Q4 | $14.6M | Buy |
2,570,700
+278,700
| +12% | +$1.58M | 0.07% | 69 |
|
|
2024
Q3 | $13.4M | Hold |
2,292,000
| – | – | 0.06% | 80 |
|
|
2024
Q2 | $18.1M | Hold |
2,292,000
| – | – | 0.08% | 70 |
|
|
2024
Q1 | $21.3M | Buy |
2,292,000
+1,000,000
| +77% | +$9.31M | 0.09% | 67 |
|
|
2023
Q4 | $10.9M | Hold |
1,292,000
| – | – | 0.05% | 75 |
|
|
2023
Q3 | $10M | Hold |
1,292,000
| – | – | 0.05% | 87 |
|
|
2023
Q2 | $14.8M | Buy |
1,292,000
+495,000
| +62% | +$5.67M | 0.07% | 83 |
|
|
2023
Q1 | $6.14M | Buy |
+797,000
| New | +$6.14M | 0.03% | 115 |
|
|
2019
Q3 | – | Sell |
-750,000
| Closed | -$20.4M | – | 116 |
|
|
2019
Q2 | $20.4M | Sell |
750,000
-250,158
| -25% | -$6.81M | 0.13% | 77 |
|
|
2019
Q1 | $19.1M | Buy |
1,000,158
+91,000
| +10% | +$1.74M | 0.14% | 72 |
|
|
2018
Q4 | $8.55M | Hold |
909,158
| – | – | 0.06% | 82 |
|
|
2018
Q3 | $17.2M | Buy |
909,158
+141,001
| +18% | +$2.67M | 0.1% | 70 |
|
|
2018
Q2 | $15M | Sell |
768,157
-121,843
| -14% | -$2.38M | 0.09% | 66 |
|
|
2018
Q1 | $16.7M | Buy |
890,000
+235,188
| +36% | +$4.42M | 0.12% | 63 |
|
|
2017
Q4 | $10.9M | Buy |
654,812
+487,147
| +291% | +$8.09M | 0.09% | 64 |
|
|
2017
Q3 | $3.45M | Buy |
+167,665
| New | +$3.45M | 0.03% | 79 |
|